Medivation's Dimebon shows long-term benefits in Alzheimer's
This article was originally published in Scrip
Executive Summary
New data on Medivation's investigational drug Dimebon show it demonstrates cognitive function benefits for up to 18 months in patients with mild-to-moderate Alzheimer's disease.